The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation

References

• Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447–1459.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035.
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–522.
   PubMed Web of Science ®Google Scholar
• Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528–e535.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525–1531.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Nishiwaki K, Nakaseko C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103(11):1835–1842.
   PubMed Web of Science ®Google Scholar
• Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised trial. Lancet Oncol. 2018;19(6):747–757.
   PubMed Web of Science ®Google Scholar
• Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61(3):650–659.
   PubMed Web of Science ®Google Scholar
• Kimura S, Imagawa J, Murai K, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7(3):e218–e225.
   PubMedGoogle Scholar
• Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298–305.
   PubMed Web of Science ®Google Scholar
• Ross DM, Masszi T, Gómez Casares MT, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018;144(5):945–954.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7–19.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025–1036.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–218.
   PubMed Web of Science ®Google Scholar
• Hughes A, Clarson J, Tang C, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129(9):1166–1176.
   PubMed Web of Science ®Google Scholar
• Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;8:469.
   PubMed Web of Science ®Google Scholar
• Rea D, Henry G, Khaznadar Z, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102(8):1368–1377.
   PubMed Web of Science ®Google Scholar
• Ilander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31(5):1108–1116.
   PubMed Web of Science ®Google Scholar
• Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101(6):717–723.
   PubMed Web of Science ®Google Scholar
• Irani YD, Hughes A, Clarson J, et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol. 2020;191(3):433–441.
   PubMed Web of Science ®Google Scholar
• Cayssials E, Jacomet F, Piccirilli N, et al. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. Br J Haematol. 2019;186(1):54–59.
   PubMed Web of Science ®Google Scholar
• Nakajima H, Zhao R, Lund TC, et al. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J Immunol. 2002;168(2):643–650.
   PubMedGoogle Scholar
• Kumagai T, Nakaseko C, Nishiwaki K, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109(1):182–192.
   PubMed Web of Science ®Google Scholar
• Vigón L, Luna A, Galán M, et al. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission. JCM. 2020;10(1):42.
   Google Scholar
• Li Y, Ding S, Liu C, et al. Abnormalities of quantities and functions of CD56bright natural killer cells in non-severe aplastic anemia. Hematology. 2019;24(1):405–412.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang S, Xin J, et al. Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res. 2019;9(10):2064–2078.
   PubMed Web of Science ®Google Scholar
• Boissel N, Rea D, Tieng V, et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule a expression in chronic myelogenous leukemia. J Immunol. 2006;176(8):5108–5116.
   PubMed Web of Science ®Google Scholar
• Chang MC, Cheng HI, Hsu K, et al. NKG2A down-Regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia. Front Immunol. 2018;9:3152.
   PubMed Web of Science ®Google Scholar
• He Y, Tian Z. NK cell education via nonclassical MHC and non-MHC ligands. Cell Mol Immunol. 2017;14(4):321–330.
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49.
   PubMed Web of Science ®Google Scholar
• Forslund E, Sohlberg E, Enqvist M, et al. Microchip-based single-cell imaging reveals that CD56dimCD57-KIR-NKG2A + NK cells have more dynamic migration associated with increased target cell conjugation and probability of killing compared to CD56dimCD57-KIR-NKG2A- NK cells. J Immunol. 2015;195(7):3374–3381.
   PubMedGoogle Scholar
• Mahaweni NM, Ehlers FAI, Sarkar S, et al. NKG2A expression is not detrimental for the anti-multiple myeloma activity of activated natural killer cells in an system mimicking the tumor microenvironment. Front Immunol. 2018;9:1415.
   PubMed Web of Science ®Google Scholar
• Hatton O, Strauss-Albee DM, Zhao NQ, et al. NKG2A-expressing natural killer cells dominate the response to autologous lymphoblastoid cells infected with Epstein-Barr virus. Front Immunol. 2016;7:607.
   PubMedGoogle Scholar